Evidence map›Paper›PMID 35116959›Full record

ArticleTranslational cancer research2019

Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma.

Peipei Xu, Rongfu Zhou, Jingyan Xu, Jian Ouyang, Xiaoyan Shao, Bing Chen

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Peipei XuDepartment of Hematology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.
Rongfu ZhouDepartment of Hematology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.
Jingyan XuDepartment of Hematology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.
Jian OuyangDepartment of Hematology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.
Xiaoyan ShaoDepartment of Hematology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.
Bing ChenDepartment of Hematology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.
Nanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBortezomib in combination with thalidomide and dexamethasone (VTD) has been widely used for newly diagnosed multiple myeloma (MM). The aim of this study was to evaluate the efficacy and safety of a new high-dose bortezomib plus thalidomide and dexamethasone as an induction and consolidation therapy regimen for MM.

methodsA total of 93 patients with previously untreated symptomatic MM were enrolled in this single-center study. In group-1, 40 patients received bortezomib 1.6 mg/m

resultsThe odds ratio rates after 2 cycles of VTD and the best response during this study were 95%

conclusionsHigh-dose bortezomib at a dose of 1.6 mg/m

Indexed as

higher single dose of bortezomibMultiple myeloma (MM)proteasome inhibitors

Identifiers

PMID35116959
PMCPMC8797627
OpenAlexW4241469660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.